- Home
- PVL vs OVID Comparison
PVL vs OVID Comparison
Compare PVL & OVID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PVL
- OVID
- Stock Information
- Founded
- PVL 2011
- OVID 2014
- Country
- PVL United States
- OVID United States
- Employees
- PVL N/A
- OVID 25
- Industry
- PVL Oil & Gas Production
- OVID Biotechnology: Pharmaceutical Preparations
- Sector
- PVL Energy
- OVID Health Care
- Exchange
- PVL Nasdaq
- OVID Nasdaq
- Market Cap
- PVL 45.5M
- OVID 49.6M
- IPO Year
- PVL N/A
- OVID 2017
- Fundamental
- Price
- PVL $1.49
- OVID $0.70
- Analyst Decision
- PVL
- OVID Strong Buy
- Analyst Count
- PVL 0
- OVID 5
- Target Price
- PVL N/A
- OVID $4.04
- AVG Volume (30 Days)
- PVL 76.9K
- OVID 385.1K
- Earning Date
- PVL 01-01-0001
- OVID 03-07-2025
- Dividend Yield
- PVL 5.75%
- OVID N/A
- EPS Growth
- PVL N/A
- OVID N/A
- EPS
- PVL 0.20
- OVID N/A
- Revenue
- PVL $3,142,081.00
- OVID $631,695.00
- Revenue This Year
- PVL N/A
- OVID $71.71
- Revenue Next Year
- PVL N/A
- OVID $741.55
- P/E Ratio
- PVL $7.80
- OVID N/A
- Revenue Growth
- PVL N/A
- OVID 113.21
- 52 Week Low
- PVL $1.03
- OVID $0.68
- 52 Week High
- PVL $1.96
- OVID $4.10
- Technical
- Relative Strength Index (RSI)
- PVL 51.56
- OVID 22.75
- Support Level
- PVL $1.38
- OVID $0.75
- Resistance Level
- PVL $1.38
- OVID $0.79
- Average True Range (ATR)
- PVL 0.05
- OVID 0.07
- MACD
- PVL 0.02
- OVID -0.02
- Stochastic Oscillator
- PVL 62.96
- OVID 1.77
About PVL Permianville Royalty Trust Trust Units
Permianville Royalty Trust is a statutory trust which holds net profits interests in the profits from the sale of oil and natural gas production the sale of oil and natural gas production from primarily non-operated assets of both conventional properties in the States of Texas, Louisiana, and New Mexico as well as unconventional assets in the Permian and Haynesville basins.
About OVID Ovid Therapeutics Inc.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential in-class mechanism of action.